SENS Sensyne Health Plc

TIDMSENS

RNS Number : 8349M

Sensyne Health PLC

24 September 2021

Notice of Preliminary Results

Oxford, UK; 24 September 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the ethical clinical AI company, will announce its Preliminary Results for the 12 months ended 30 April 2021 on Friday, 1(st) October.

Lord (Paul) Drayson, Chief Executive Officer, and Richard Pye, Chief Financial Officer, will host a virtual briefing for analysts and investors at 13:00 GMT / 08:00 ET on the day of the results.

Details of the webcast, and the presentation slides, will be available via the Company's website. For more details, please contact CSCSensynehealth@consilium-comms.com.

-ENDS-

For more information please contact:

 
  Sensyne Health ( www.sensynehealth.com             +44 (0) 330 058 
   )                                                  1845 
  Lord (Paul) Drayson PhD FREng, Chief Executive 
   Officer 
  Dr Richard Pye, Chief Financial Officer 
  Peel Hunt LLP (Nominated Adviser and Joint         + 44 (0) 20 7418 
   Broker)                                            8900 
  Dr Christopher Golden 
  James Steel 
  Oliver Jackson 
                                                     + 44 (0) 20 3100 
  Liberum (Joint Broker)                              2000 
  Bidhi Bhoma 
  Euan Brown 
  Consilium Strategic Communications                 +44 (0) 7780600290 
  Mary-Jane Elliott 
  Jessica Hodgson 
  Davide Salvi 
  CSCSensynehealth@consilium-comms.com 
 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFZGZLZFFGMZZ

(END) Dow Jones Newswires

September 24, 2021 02:00 ET (06:00 GMT)

Sensyne Health (LSE:SENS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Sensyne Health (LSE:SENS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024